Acetylcysteine in IPF: The knockout blow?

The Lancet Respiratory Medicine

Volumn 4, Issue 6, 2016, Pages 420-421

  Wijsenbeek, Marlies S ^a   Collard, Harold R ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; NINTEDANIB; PIRFENIDONE; PLACEBO; PREDNISONE; PYRIDONE DERIVATIVE;

CLINICAL PRACTICE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FIBROSING ALVEOLITIS; FOLLOW UP; FORCED VITAL CAPACITY; GENE; GENOTYPE; HUMAN; NOTE; PHARMACOGENOMICS; PHOTOSENSITIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; TOLLIP GENE;

ACETYLCYSTEINE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PYRIDONES;

EID: 84965038716     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(16)30085-6     Document Type: Note

References (10)

1. Meyer A, Buhl R, Magnussen H The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis. Eur Respir J 1994, 7:431-436.
2. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005, 353:2229-2242.
3. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183:788-824.
4. Raghu G, Anstrom KJ, King TE, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012, 366:1968-1977. for the Idiopathic Pulmonary Fibrosis Clinical Research Network.
5. Martinez FJ, de Andrade JA, Anstrom KJ, et al. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2014, 370:2093-2101. for the Idiopathic Pulmonary Fibrosis Clinical Research Network.
6. Oldham JM, Ma SF, Martinez FJ, et al. TOLLIP, MUC5B, and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2015, 192:1475-1482.
7. Raghu G, Rochwerg B, Zhang Y, et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: treatment of idiopathic pulmonary fibrosis. an update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med 2015, 192:e3-19.
8. King TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014, 370:2083-2092.
9. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014, 370:2071-2082.
10. Behr J, Bendstrup E, Crestani B, et al. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med 2016, published online May 5. http://dx.doi.org/10.1016/S2213-2600(16)30044-3.